China has granted the first approval for a domestically-originated oral antiviral drug for COVID-19, as the country faces rising economic pressures as cases and infections continue to flare up around the nation.
Azvudine, a novel nucleoside reverse transcriptase inhibitor originally developed by little-known Henan Genuine Biotech for HIV, was granted an emergency use authorization in the new setting on 25 July
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?